Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H3BrO3 |
Molecular Weight | 166.958 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C(=O)CBr
InChI
InChIKey=PRRZDZJYSJLDBS-UHFFFAOYSA-N
InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)
Molecular Formula | C3H3BrO3 |
Molecular Weight | 166.958 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Bromopyruvate is an halogenated analogue of pyruvic acid known as an alkylating agent reacting with thiol groups of many proteins. Bromopyruvate exerts anticancer action. It is based on the impairment of energy metabolism of tumor cells by inhibiting enzymes in the glycolysis pathway (hexokinase II, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase) and the oxidative phosphorylation (succinate dehydrogenase). Bromopyruvate induces endoplasmic reticulum stress, inhibits global protein synthesis further contributing to cancer cell death. Treatment with bromopyruvate has been administered in several cancer type models both in vitro and in vivo, either alone or in combination with other anticancer therapeutic approaches. These studies clearly demonstrate bromopyruvate broad action against multiple cancer types. This compound has also antifungal and antiparasitic activity.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: 3662629.0 Gene Symbol: Tb10.6k15.3850 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8429041 |
2.67 µM [IC50] | ||
Target ID: O00187|||Q9H498 Gene ID: 10747.0 Gene Symbol: MASP2 Target Organism: Homo sapiens (Human) Sources: https://adisinsight.springer.com/drugs/800038438 |
|||
Target ID: GO:0045254 | pyruvate dehydrogenase complex Sources: https://adisinsight.springer.com/drugs/800038438 |
PubMed
Title | Date | PubMed |
---|---|---|
2-Methylisocitrate lyases from the bacterium Escherichia coli and the filamentous fungus Aspergillus nidulans: characterization and comparison of both enzymes. | 2001 Jun |
|
Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate. | 2001 Nov |
|
Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. | 2001 Nov 8 |
|
Investigation of red blood cell carbonic anhydrase, glucose 6-phosphate dehydrogenase, hexokinase enzyme activities, and zinc concentration in patients with hyperthyroid diseases. | 2002 Feb-May |
|
An absolute requirement of fructose 1,6-bisphosphate for the Lactobacillus casei L-lactate dehydrogenase activity induced by a single amino acid substitution. | 2002 Jan |
|
Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. | 2002 Jul 15 |
|
Lack of antifertility properties of novel halogenated glycolytic inhibitors and the urinary excretion and metabolism of 1,6-dichloro-1,6-dideoxy-D-fructofuranose in the male rat. | 2002 Jun |
|
3-Bromopyruvate kills cancer cells in animals. | 2002 Sep |
|
Energy blocker to treat liver cancer. | 2002 Sep 15 |
|
Glycolytic ATP production regulates muscarinic cation currents in guinea-pig ileum. | 2003 Apr |
|
A new approach to therapy for hepatocellular carcinoma? | 2003 Feb |
|
Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. | 2003 Jan 17 |
|
Crystal structure of 2-methylisocitrate lyase (PrpB) from Escherichia coli and modelling of its ligand bound active centre. | 2003 May 2 |
|
Carbonic anhydrase in mammalian vascular smooth muscle. | 2004 Aug |
|
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. | 2005 Jan 15 |
|
Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. | 2005 Mar |
|
Colony-stimulating factor-1 requires PI3-kinase-mediated metabolism for proliferation and survival in myeloid cells. | 2006 Nov |
|
[Expression of hexokinase-II gene in human colon cancer cells and the therapeutic significance of inhibition thereof]. | 2007 Apr 17 |
|
The cancer cell's "power plants" as promising therapeutic targets: an overview. | 2007 Feb |
|
Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. | 2007 Jun |
|
Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. | 2007 Sep |
|
Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. | 2008 |
|
Hamster sperm capacitation: role of pyruvate dehydrogenase A and dihydrolipoamide dehydrogenase. | 2008 Aug |
|
Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA. | 2008 Dec |
|
Revealing targeted therapy for human cancer by gene module maps. | 2008 Jan 15 |
|
The role of glucose metabolism and glucose-associated signalling in cancer. | 2008 Jan 18 |
|
A novel strategy involved in [corrected] anti-oxidative defense: the conversion of NADH into NADPH by a metabolic network. | 2008 Jul 16 |
|
Strategies for molecular imaging dementia and neurodegenerative diseases. | 2008 Jun |
|
Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. | 2008 Mar 15 |
|
Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. | 2008 Nov |
|
Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. | 2008 Oct |
|
Hexokinase inhibitor screening based on adenosine 5'-diphosphate determination by electrophoretically mediated microanalysis. | 2009 Apr |
|
Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. | 2009 Apr |
|
Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. | 2009 Feb |
|
Senescence induction; a possible cancer therapy. | 2009 Jan 8 |
|
Mitochondria and energetic depression in cell pathophysiology. | 2009 May 19 |
|
The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. | 2009 Nov-Dec |
|
Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson's disease. | 2009 Oct |
|
Role of the mitochondrion in programmed necrosis. | 2010 |
|
The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. | 2010 Apr |
|
3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. | 2010 Aug |
|
Fully automated continuous flow synthesis of highly functionalized imidazo[1,2-a] heterocycles. | 2010 Feb 5 |
|
Cancer as a metabolic disease. | 2010 Jan 27 |
|
Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. | 2010 Jul |
|
Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. | 2011 Aug 1 |
|
Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation. | 2012 May |
|
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. | 2013 Jan |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:40:11 UTC 2023
by
admin
on
Fri Dec 15 19:40:11 UTC 2023
|
Record UNII |
63JMV04GRK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
894722
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
||
|
FDA ORPHAN DRUG |
390013
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
||
|
FDA ORPHAN DRUG |
430514
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
||
|
FDA ORPHAN DRUG |
736920
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
70684
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
11731
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
Bromopyruvate
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
C017092
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
62343
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
DTXSID7040940
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
214-206-5
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
100000177177
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
1113-59-3
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY | |||
|
63JMV04GRK
Created by
admin on Fri Dec 15 19:40:11 UTC 2023 , Edited by admin on Fri Dec 15 19:40:11 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
Expression higher in tumor cells
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|